Long-term safety of duloxetine during open-label compassionate use treatment of patients who completed previous duloxetine clinical trials

Current Medical Research and Opinion

Volumn 26, Issue 11, 2010, Pages 2643-2651

  Pangallo, Beth A ^a   Zhang, Qi ^a   Desaiah, Durisala ^a   Perahia, David G S ^a,b   Detke, Michael J ^c,d,e   Kennedy, Sidney H ^f  

^a ELI LILLY AND COMPANY   (United States)

^b Gordon Hospital   (United Kingdom)

^c Medavante Corporation   (United States)

^d MCLEAN HOSPITAL   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

Compassionate use; Diabetic peripheral neuropathic pain; Duloxetine; Fibromyalgia; General anxiety disorder; Major depressive disorder

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; DULOXETINE; IBUPROFEN; PARACETAMOL;

ADULT; AMPUTATION; ANXIETY; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; BURSITIS; CELLULITIS; CLINICAL TRIAL; COMPASSIONATE USE; CONSTIPATION; COUGHING; DIABETIC NEUROPATHY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FIBROMYALGIA; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHIDROSIS; HYPERTENSION; INFECTION; INSOMNIA; LIMB PAIN; LONG TERM CARE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; MUSCULOSKELETAL PAIN; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; OPEN STUDY; OSTEOARTHRITIS; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PULSE RATE; RHINOPHARYNGITIS; SIDE EFFECT; SKIN ULCER; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS; COMPASSIONATE USE TRIALS; DEPRESSIVE DISORDER, MAJOR; DRUG TOXICITY; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); THIOPHENES; TIME;

EID: 77958126033     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.522157     Document Type: Article

References (30)

1. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-15
2. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383-90
3. Perahia DG, Maina G, Thase ME, et al. Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:706-16
4. Kornstein SG, Russell JM, Spann ME, et al. Duloxetine in the treatment of generalized anxiety disorder. Expert Rev Neurother 2009;9:155-65
5. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6:346-56
6. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006;67: 1411-20
7. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004; 50:2974-84
8. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5-15
9. Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008;136:432-44
10. Chappell AS, Ossanna MJ, Liu-Seifert H, et al. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-Week, randomized, placebo-controlled trial. Pain 2009;146:253-60
11. Skljarevski V, Desaiah D, Liu-Seifert H, et al. Efficacy and safety of duloxetine in patients with chronic low back pain. Spine 2010;35:E578-85
12. Skljarevski V, Ossanna M, Liu-Seifert H, et al. A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. Eur J Neurol. 2009;16:1041-48
13. Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002;36: 106-32
14. Acharya N, Rosen AS, Polzer JP, et al. Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder. J Clin Psychopharmacol 2006;26:587-94
15. Hudson JI, Wohlreich MM, Kajdasz DK, et al. Safety and tolerability of dulox-etine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol 2005; 20:327-41
16. Gahimer J, Wernicke J, Yalcin I, et al. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin 2007;23:175-84
17. Pederson AG. Citalopram and suicidality in adult major depression and anxiety disorders. Nord J Psychiatry 2006;60:392-99
18. Wagner W, Plekkenpol B, Gray TE, et al. Review of fluvoxamine safety database. Drugs 1992;43(Suppl. 2):48-53
19. Lane PW. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharm Stat 2008;7:93-06
20. Prakash A, Risser RC, Mallincrodt CH. The impact of analytic method on interpretation of outcomes in longitudinal clinical trials. Int J Clin Pract 2008;62:1147-58
21. Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects models. J Biopharm Stat 2001;11:9-21
22. Mallinckrodt CH, Clark WS, David SR. Type I error rates from mixed effects model repeated measures versus with fixed effects ANOVA with missing values imputed via last observation carried forward. Drug Inf J 2001; 35:1215-25
23. Mallinckrodt CH, Kaiser CJ, Watkin JG, et al. Type I error rates from likelihood-based repeated measures analyses of incomplete longitudinal data. Pharm Stat 2004;3:171-86
24. Mallinckrodt CH, Kaiser CJ, Watkin JG, et al. The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVA. Clin Trials 2004;1:477-48
25. Mallinckrodt CH, Lane PW, Schnell D, et al. Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials. Drug Inf J 2008;42:303-19
26. Mallinckrodt CH, Watkin JG, Molenberghs G, et al. Choice of the primary analysis in longitudinal clinical trials. Pharm Stat 2004;3:161-69
27. Goldman LS, Alexander RC, Luchins DJ. Monoamine oxidase inhibitors and tricyclic antidepressants: comparison of their cardiovascular effects. J Clin Psychiatry 1986;47:225-29
28. Wong DT, Bymaster FP. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype? Prog Drug Res 2002;58:169-22
29. Raskin J, Wang F, Pritchett YL, et al. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Med 2006;7:373-85
30. Skljarevski V, Desaiah D, Zhang Q, et al. Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain. Diabetes Metab Res Rev 2009;25:623-31